Progress in antisense technology

Crooke, Stanley T.

doi:10.1146/annurev.med.55.091902.104408

Cited by 417RNA Interference and Gene DeliveryDNA and Nucleic Acid ChemistryRNA Research and Splicing

Progress in antisense technology

Crooke, Stanley T.·2004·Annual Review of Medicine

DOI 10.1146/annurev.med.55.091902.104408

Open this paper in CoChat — free account

Abstract

Antisense technology exploits oligonucleotide analogs to bind to target RNAs via Watson-Crick hybridization. Once bound, the antisense agent either disables or induces the degradation of the target RNA. Antisense agents can also alter splicing. During the past decade, much has been learned about the basic mechanisms of antisense, the medicinal chemistry, and the pharmacologic, pharmacokinetic, and toxicologic properties of antisense molecules. Antisense technology has proven valuable in gene functionalization and target validation. With one drug marketed, Vitravenetm, and approximately 20 antisense drugs in clinical development, it appears that antisense drugs may prove important in the treatment of a wide range of diseases.

Integrity signals

Registry

Crossref · 10.1146/annurev.med.55.091902.104408

Cites

241 of 241 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PKCε antisense oligonucleotide improves hepatic insulin sensitivity and insulin signalling in rats fed a high-fat diet for 3 days, despite equal fat and diacylglycerol accumulation.
“Though fat accumulation, and specifically diacylglycerol accumulation, was equal in all groups, the PKCε antisense oligonucleotide improved hepatic insulin sensitivity and insulin signalling.”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [107]

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456 · see citing works
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508 · see citing works
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718 · see citing works
RNAi
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,667 · see citing works
Predicting DNA duplex stability from the base sequence
Breslauer, K. J., Frank, R., Blöcker, H., & Marky, L. A. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.3746 · Cited by 1,837 · see citing works
Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792 · see citing works
Functional genomic analysis of C. elegans chromosome I by systematic RNA interference
Fraser, A. G., Kamath, R. S., Zipperlen, P., Martinez-Campos, M., Sohrmann, M., & Ahringer, J. (2000) · Nature · doi:10.1038/35042517 · Cited by 1,720 · see citing works
Anti-cancer Drug Design
SISSAOUI, M. (2018) · Archives of Clinical Microbiology · doi:10.4172/1989-8436-c3-011 · Cited by 1,352 · see citing works
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C., & Cheng, Y. C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,303 · see citing works
Morpholino Antisense Oligomers: Design, Preparation, and Properties
Summerton, J. E., & Weller, D. D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,115 · see citing works
Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems
Caplen, N. J., Parrish, S., Imani, F., Fire, A. Z., & Morgan, R. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171251798 · Cited by 1,042 · see citing works
Functional genomic analysis of cell division in C. elegans using RNAi of genes on chromosome III
Gönczy, P., Echeverri, C. J., Oegema, K., Coulson, A. R., Jones, S. J. M., Copley, R. R., Duperon, J., Oegema, J., Brehm, M., Cassin, E., et al. (2000) · Nature · doi:10.1038/35042526 · Cited by 858 · see citing works
Targeted mRNA degradation by double-stranded RNA in vitroPreprint
Tuschl, T., Zamore, P. D., Lehmann, R., Bartel, D. P., & Sharp, P. A. (1999) · Genes & Development · doi:10.1101/gad.13.24.3191 · Cited by 843 · see citing works
Evaluation of 2‘-modified oligonucleotides containing 2‘-deoxy gaps as antisense inhibitors of gene expression
Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D. P. C., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., & Freier, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85268-7 · Cited by 779 · see citing works
siRNA-directed inhibition of HIV-1 infection
Novina, C. D., Murray, M. F., Dykxhoorn, D. M., Beresford, P. J., Riess, J. W., Lee, S., Collman, R. G., Lieberman, J., Shankar, P., & Sharp, P. A. (2002) · Nature Medicine · doi:10.1038/nm725 · Cited by 775 · see citing works
Characterization of oligonucleotide transport into living cells.
Loke, S. L., Stein, C. A., Zhang, X. H., Mori, K., Nakanishi, M., Subasinghe, C., Cohen, J. S., & Neckers, L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3474 · Cited by 734 · see citing works
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo
Simons, M., Edelman, E. R., DeKeyser, J.-L., Langer, R., & ROSENBERG, R. D. (1992) · Nature · doi:10.1038/359067a0 · Cited by 731 · see citing works
CpG DNA Is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen
Davis, H. L., Weeranta, R., Waldschmidt, T. J., Tygrett, L. T., Schorr, J., & Krieg, A. Μ. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.2.870 · Cited by 676 · see citing works
Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.
Bennett, C. F., Chiang, M. Y., Chan, H. E. H., Shoemaker, J. E., & Mirabelli, C. K. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09229-6 · Cited by 612 · see citing works
Antisense Research and Applications
Agrawal, S., & Crooke, S. T. (1993) · Medical Entomology and Zoology · Cited by 610 · see citing works
Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells
Hartmann, G., & Krieg, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.944 · Cited by 605 · see citing works
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
Agrawal, S., Temsamani, J., & Tang, J. Y. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7595 · Cited by 564 · see citing works
Antisense and Antigene Properties of Peptide Nucleic Acids
Hanvey, J. C., Peffer, N. J., Bisi, J., Thomson, S. A., Cadilla, R., Josey, J. A., Ricca, D. J., Hassman, C. F., Bonham, M. A., Au, K. G., et al. (1992) · Science · doi:10.1126/science.1279811 · Cited by 534 · see citing works
Modulation of Anxiety and Neuropeptide Y-Y1 Receptors by Antisense Oligodeoxynucleotides
Wahlestedt, C., Pich, E. M., Koob, G. F., Yee, F., & Heilig, M. A. (1993) · Science · doi:10.1126/science.8380941 · Cited by 524 · see citing works
Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.
Chiang, M. Y.-N., Chan, H., Zounes, M. A., Freier, S., Lima, W. F., & Bennett, C. F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55250-9 · Cited by 463 · see citing works
Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents
Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., & Baker, B. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210326200 · Cited by 461 · see citing works
Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma
Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F. I., Stefano, F. D., & Cotter, F. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1812 · Cited by 454 · see citing works
Role of RNase H in hybrid-arrested translation by antisense oligonucleotides.
Walder, R. Y., & Walder, J. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5011 · Cited by 453 · see citing works
Genetic Requirements for Inheritance of RNAi in C. elegans
Grishok, A., Tabara, H., & Mello, C. C. (2000) · Science · doi:10.1126/science.287.5462.2494 · Cited by 450 · see citing works
Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
Monia, B. P., Johnston, J. F., Geiger, T. M., Muller, M., & Fabbro, D. (1996) · Nature Medicine · doi:10.1038/nm0696-668 · Cited by 447 · see citing works
Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo
Osen‐Sand, A., Catsicas, M., Staple, J. K., Jones, K. A., Ayala, G., Knowles, J., Grenningloh, G., & Catsicas, S. (1993) · Nature · doi:10.1038/364445a0 · Cited by 442 · see citing works
Uniformly modified 2'-deoxy-2'-fluoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets
Kawasaki, A. M., Casper, M. D., Freier, S. M., Lesnik, E. A., Zounes, M. C., Cummins, L. L., Gonzalez, C., & Cook, P. D. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00059a007 · Cited by 439 · see citing works
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Domiński, Z., & Kole, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8673 · Cited by 426 · see citing works
Inhibition of DNA Binding Proteins by Oligonucleotide-Directed Triple Helix Formation
Maher, L. J., Wold, B. J., & Dervan, P. B. (1989) · Science · doi:10.1126/science.2549631 · Cited by 414 · see citing works
Antisense Gene Inhibition by Oligonucleotides Containing C-5 Propyne Pyrimidines
Wagner, R. W., Matteucci, M. D., Lewis, J. G., Gutierrez, A. J., Moulds, C., & Froehler, B. C. (1993) · Science · doi:10.1126/science.7684856 · Cited by 406 · see citing works
Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.
Zamecnik, P. C., Goodchild, J., Taguchi, Y., & Sarin, P. S. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4143 · Cited by 400 · see citing works
Site specific enzymatic cleavage of RNA
Donis-Keller, H. (1979) · Nucleic Acids Research · doi:10.1093/nar/7.1.179 · Cited by 399 · see citing works
Extension of the Life-Span of Human Endothelial Cells by an Interleukin-1αAntisense Oligomer
Maier, J. A. M., Voulalas, P. J., Roeder, D., & Maciag, T. (1990) · Science · doi:10.1126/science.2218499 · Cited by 397 · see citing works
A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis
Der, S. D., Yang, Y.-L., Weissmann, C., & Williams, B. R. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3279 · Cited by 389 · see citing works
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
Yacyshyn, B., Bowen-Yacyshyn, M. B., Jewell, L. D., Tami, J. A., Bennett, C. F., Kisner, D. L., & Shanahan, W. R. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70418-4 · Cited by 380 · see citing works
Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
Messina, J. P., Gilkeson, G. S., & Pisetsky, D. S. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.6.1759 · Cited by 374 · see citing works
Real time detection of DNA⋅RNA hybridization in living cells
Sokol, D. L., Zhang, X., Lu, P., & Gewirtz, A. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11538 · Cited by 374 · see citing works
Estimation of the aqueous solubility I: Application to organic nonelectrolytes
Jain, N., & Yalkowsky, S. H. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200102)90:2 · Cited by 368 · see citing works
Ancient Pathways Programmed by Small RNAs
Zamore, P. D. (2002) · Science · doi:10.1126/science.1072457 · Cited by 360 · see citing works
Failure to produce mitochondrial DNA results in embryonic lethality in Rnaseh1 null mice
Cerritelli, S. M., Frolova, E. G., Feng, C., Grinberg, A., Love, P. E., & Crouch, R. J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00088-1 · Cited by 358 · see citing works
Base pairing involving deoxyinosine: implications for probe design
Martin, F. H., Castro, M. M., Aboul‐ela, F., & Tinoco, I. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.24.8927 · Cited by 342 · see citing works
Ribonucleases : structures and functions
D’Alessio, G., & Riordan, J. F. (1997) · Cited by 336 · see citing works
Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site.
Lemaitre, M. M., Bayard, B., & Lebleu, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.3.648 · Cited by 330 · see citing works
The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism.
Burgess, T. L., Fisher, E. F., Ross, S. L., BREADY, J. V., Qian, Y., Bayewitch, L. A., Cohen, A. M., Herrera, C., Hu, S., & Kramer, T. B. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.4051 · Cited by 320 · see citing works
Combinatorially selected guanosine-quartet structureis a potent inhibitor of human immunodeficiency virus envelope-mediated cellfusion.
Wyatt, J. R., Vickers, T. A., Roberson, J. L., Buckheit, R. W., Klimkait, T., DeBaets, E. L., Davis, P. W., Rayner, B., IMBACH, J. ‐., & Ecker, D. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1356 · Cited by 301 · see citing works
Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5.
Smith, C. C., Aurelian, L., Reddy, M. P., Miller, P. S., & Ts’o, P. O. P. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.9.2787 · Cited by 297 · see citing works
Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.
Dean, N. M., McKay, R. A., Condon, T. P., & Bennett, C. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34023-1 · Cited by 291 · see citing works
Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.
Agrawal, S., Goodchild, J., Civeira, M. P., Thornton, A., Sarin, P. S., & Zamecnik, P. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7079 · Cited by 291 · see citing works
Pharmacokinetic Properties of 2′-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
Geary, R. S., Watanabe, T. A., Truong, L., Freier, S., Lesnik, E. A., Sioufi, N. B., Sasmor, H. M., Manoharan, M., & Levin, A. A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38831-7 · Cited by 289 · see citing works
In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits
Griffin, L., Tidmarsh, G. F., Bock, L. C., Toole, J. J., & Leung, L. L. K. (1993) · Blood · doi:10.1182/blood.v81.12.3271.3271 · Cited by 285 · see citing works
Activation of human B cells by phosphorothioate oligodeoxynucleotides.
Liang, H., Nishioka, Y., Reich, C. F., Pisetsky, D. S., & Lipsky, P. E. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118894 · Cited by 284 · see citing works
Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-kappa B
Kitajima, I., Shinohara, T., Bilakovics, J. M., Brown, D., Xu, X., & Nerenberg, M. I. (1993) · Science · doi:10.1126/science.8456277 · Cited by 279 · see citing works
Highly efficient chemical synthesis of 2′-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases
Sproat, B. S., Lamond, A. I., Beijer, B., Neuner, P., & Ryder, U. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.9.3373 · Cited by 271 · see citing works
Antisense Drug Technology
(2010) · CRC Press eBooks · doi:10.1201/9781420002546 · Cited by 270 · see citing works
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis
Zhang, H., Cook, J., Nickel, J., Yu, R. Z., Stecker, K., Myers, K. J., & Dean, N. M. (2000) · Nature Biotechnology · doi:10.1038/78475 · Cited by 268 · see citing works
Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.
Sands, H., Gorey‐Feret, L. J., Cocuzza, A. J., Hobbs, F. W., Chidester, D. R., & Trainor, G. L. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10208-3 · Cited by 267 · see citing works
Antisense oligonucleotide strategies in neuropharmacology
Wahlestedt, C. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90107-4 · Cited by 267 · see citing works
Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.
Cossum, P. A., Sasmor, H. M., Dellinger, D., Truong, L., Cummins, L. M., Owens, S. R., Markham, P. M., Shea, J. P., & Crooke, S. T. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39459-0 · Cited by 265 · see citing works
Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression.
Higgins-Sochaski, K. A., Perez, J. R., Coleman, T. A., Dorshkind, K. A., McComas, W. A., Sarmiento, U. M., Rosen, C. A., & Narayanan, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.9901 · Cited by 261 · see citing works
DNA antisense therapy for asthma in an animal model
Nyce, J. W., & Metzger, W. J. (1997) · Nature · doi:10.1038/385721a0 · Cited by 258 · see citing works
Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.
Wang, S., Lee, R. J., Cauchon, G., Gorenstein, D. G., & Low, P. S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3318 · Cited by 257 · see citing works
α-Oligodeoxynucleotide stability in serum, subcellular extracts and culture media
Bacon, T. A., Morvan, F., Rayner, B., Imbach, J., & Wickstrom, E. (1988) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(88)90065-6 · Cited by 255 · see citing works
Effects of phosphorothioate capping on antivense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection
Hoke, G. D., Draper, K. G., Freier, S. M., Gonzalez, C., Brown‐Driver, V., Zounes, M. C., & Ecker, D. J. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.20.5743 · Cited by 248 · see citing works
Inhibition of protein kinase B/Akt
Hill, M. M. C., & Hemmings, B. A. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00193-6 · Cited by 246 · see citing works
Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.
Dean, N. M., & McKay, R. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11762 · Cited by 244 · see citing works
The use of single-stranded DNA and RNase H to promote quantitative ‘hybrid arrest of translation’ of mRNA/DNA hybrids in reticulocyte lysate cell-free translations
Minshull, J., & Hunt, T. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.16.6433 · Cited by 244 · see citing works
Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the Monkey
Galbraith, W. M., Hobson, W. C., Giclas, P. C., Schechter, P. J., & Agrawal, S. (1994) · Antisense Research and Development · doi:10.1089/ard.1994.4.201 · Cited by 238 · see citing works
Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides
Cazenave, C., Stein, C. A., Loreau, N., Thuong, N. T., Neckers, L., Subasinghe, C., Hélène, C., Cohen, J. S., & Toulmé, J. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.11.4255 · Cited by 238 · see citing works
Ein neuer Zugang zu 2′‐O‐Alkylribonucleosiden und Eigenschaften deren Oligonucleotide
Martin, P. (1995) · Helvetica Chimica Acta · doi:10.1002/hlca.19950780219 · Cited by 235 · see citing works
Oligodeoxynucleotide stability in subcellular extracts and culture media
Wickstrom, E. (1986) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(86)90021-7 · Cited by 234 · see citing works
Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression
Ghosh, M. K., & Cohen, J. S. (1992) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60574-7 · Cited by 233 · see citing works
Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.
Gao, W., Han, F. S., Storm, C., Egan, W., & Cheng, Y.-T. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08861-3 · Cited by 232 · see citing works
dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference
Caplen, N. J., Fleenor, J., Fire, A. Z., & Morgan, R. A. (2000) · Gene · doi:10.1016/s0378-1119(00)00224-9 · Cited by 232 · see citing works
Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid
Campbell, J. M., Bacon, T. A., & Wickstrom, E. (1990) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(90)90084-p · Cited by 230 · see citing works
Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
Crooke, S. T., Graham, M. J., Zuckerman, J. E., Brooks, D., Conklin, B., Cummins, L. L., Greig, M. J., Guinosso, C. J., Kornbrust, D. J., Manoharan, M., et al. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12951-0 · Cited by 227 · see citing works
Implication of RNA structure on antisense oligonucleotide hybridization kinetics
Lima, W. F., Monia, B. P., Ecker, D. J., & Freier, S. M. (1992) · Biochemistry · doi:10.1021/bi00163a013 · Cited by 226 · see citing works
Burger's Medicinal Chemistry and Drug Discovery
Shader, R. I. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199510000-00018 · Cited by 226 · see citing works
Activation of the Alternative Pathway of Complement by a Phosphorothioate Oligonucleotide: Potential Mechanism of Action
Henry, S. P., Giclas, P. C., Leeds, J., Pangburn, M. K., Auletta, C. S., Levin, A. A., & Kornbrust, D. J. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36667-4 · Cited by 204 · see citing works
Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region
Azad, R. F., Brown‐Driver, V., Tanaka, K., Crooke, R. M., & Anderson, K. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1945 · Cited by 203 · see citing works
Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide
Majumdar, C., Stein, C. A., Cohen, J. S., Broder, S. E., & Wilson, S. H. (1989) · Biochemistry · doi:10.1021/bi00429a060 · Cited by 187 · see citing works
Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes
Crooke, S. T., Lemonidis, K. M., Neilson, L. I., Griffey, R. H., Lesnik, E. A., & Monia, B. P. (1995) · Biochemical Journal · doi:10.1042/bj3120599 · Cited by 186 · see citing works
Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries
Ho, S. P., Bao, Y., Lesher, T., Malhotra, R., Ma, L. Y., Fluharty, S. J., & Sakai, R. R. (1998) · Nature Biotechnology · doi:10.1038/nbt0198-59 · Cited by 186 · see citing works
RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds
Furdon, P. J., Domiński, Z., & Kole, R. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.22.9193 · Cited by 178 · see citing works
Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha-
Monia, B. P., Johnston, J. F., Sasmor, H. M., & Cummins, L. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.24.14533 · Cited by 177 · see citing works
Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean, N. S., McKay, R. A., Miraglia, L. J., Howard, R., Cooper, S. R., Giddings, J., Nicklin, P. L., Meister, L., Ziel, R., Geiger, T. M., et al. (1996) · PubMed · Cited by 175 · see citing works
Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
Skórski, T., Nieborowska-Skorska, M., Nicolaides, N. C., Szczylik, C. A., Iversen, P. L., Iozzo, R. V., Zon, G., & Calabretta, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4504 · Cited by 172 · see citing works
Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer
Nemunaitis, J. J., Holmlund, J., Kraynak, M. A., Richards, D., Bruce, J., Ognoskie, N., Kwoh, T. J., Geary, R. S., Dorr, A., Hoff, D. V., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3586 · Cited by 172 · see citing works
Tricyclic 2'-Deoxycytidine Analogs: Syntheses and Incorporation into Oligodeoxynucleotides Which Have Enhanced Binding to Complementary RNA
Lin, K., Jones, R. J., & Matteucci, M. D. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00118a026 · Cited by 164 · see citing works
Properties of Cloned and Expressed Human RNase H1
Wu, H., Lima, W. F., & Crooke, S. T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.40.28270 · Cited by 159 · see citing works
Therapeutic Applications Of Oligonucleotides
Crooke, S. T. (1992) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.32.1.329 · Cited by 157 · see citing works
Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues.
Butler, M., Stecker, K., & Bennett, C. F. (1997) · PubMed · Cited by 152 · see citing works
Chemically Modified Oligonucleotides Exhibit Decreased Immune Stimulation in Mice
Henry, S. P., Stecker, K., Brooks, D., Monteith, D., Conklin, B., & Bennett, C. F. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35315-7 · Cited by 152 · see citing works
Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide
McManaway, M. E., Alnasser, A., Shiramizu, B. T., Goldschmidts, W., Bhatia, K. G., MAGRATH, I. T., Neckers, L., Loke, S. L., Redner, R. L., & Huber, B. E. (1990) · The Lancet · doi:10.1016/0140-6736(90)90934-w · Cited by 150 · see citing works
Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial
Bayever, E., Iversen, P. L., Bishop, M. R., Sharp, J. G., Tewary, H. K., Arneson, M. A., Pirruccello, S. J., Ruddon, R. W., Kessinger, A., Zon, G., et al. (1993) · Antisense Research and Development · doi:10.1089/ard.1993.3.383 · Cited by 149 · see citing works
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.
Yuen, A. R., Halsey, J., Fisher, G. A., Holmlund, J. T., Geary, R. S., Kwoh, T. J., Dorr, A., & Sikic, B. I. (1999) · PubMed · Cited by 148 · see citing works
Prothymosin alpha antisense oligomers inhibit myeloma cell division.
Sburlati, A. R., Manrow, R. E., & Berger, S. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.1.253 · Cited by 142 · see citing works
Translation arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length
Haeuptle, M. T., Frank, R. W., & Dobberstein, B. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.3.1427 · Cited by 141 · see citing works
In Vivo Distribution and Metabolism of a Phosphorothioate Oligonucleotide within Rat Liver after Intravenous Administration
Graham, M. J., Crooke, S. T., Monteith, D., Cooper, S. R., Lemonidis, K. M., Stecker, K., Martin, M. J., & Crooke, R. M. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37605-0 · Cited by 140 · see citing works
A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth
Nesterova, M., & Cho‐Chung, Y. S. (1995) · Nature Medicine · doi:10.1038/nm0695-528 · Cited by 138 · see citing works
Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4.
Kulka, M., Smith, C. C., Aurelian, L., Fishelevich, R., Meade, K. S., Miller, P. S., & Ts’o, P. O. P. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.6868 · Cited by 137 · see citing works
Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration
Agrawal, S., Zhang, X., Lu, Z., Zhao, H., Tamburin, J. M., Van, J., Cai, H., Diasio, R. B., Habuš, I., Jiang, Z., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00160-2 · Cited by 136 · see citing works
Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures
Giles, R. V., & TIDD, D. M. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.4.763 · Cited by 135 · see citing works
Interferon Induction Increased through Chemical Modification of a Synthetic Polyribonucleotide
Clercq, E. D., Eckstein, F., & Merigan, T. C. (1969) · Science · doi:10.1126/science.165.3898.1137 · Cited by 135 · see citing works
Crystal structure of Escherichia coli RNase HI in complex with Mg2+ at 2.8 Å resolution: Proof for a single Mg2+‐binding site
Katayanagi, K., Okumura, M., & Morikawa, K. (1993) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.340170402 · Cited by 135 · see citing works
Phase I Safety and Pharmacokinetic Profile of an Intercellular Adhesion Molecule-1 Antisense Oligodeoxynucleotide (ISIS 2302)
Glover, J. M., Leeds, J. M., Mant, T., Amin, D., Kisner, D. L., Zuckerman, J. E., Geary, R. S., Levin, A. A., & Shanahan, W. R. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36939-3 · Cited by 135 · see citing works
Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy
Rappaport, J., Hanss, B. G., Kopp, J. B., Copeland, T. D., Bruggeman, L. A., Coffman, T. M., & Klotman, P. E. (1995) · Kidney International · doi:10.1038/ki.1995.205 · Cited by 132 · see citing works
Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent
Zerial, A., Thuong, N. T., & Hélène, C. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.23.9909 · Cited by 130 · see citing works
Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element
Vickers, T. A., Baker, B. F., Cook, P. D., Zounes, M. C., Buckheit, R. W., Germany, J., & Ecker, D. J. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.12.3359 · Cited by 130 · see citing works
Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects*
Zhang, R., Yan, J., Shahinian, H., Amin, G., Lu, Z., Liu, T., Saag, M. S., Jiang, Z., Temsamani, J., Martin, R. R., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90071-3 · Cited by 129 · see citing works
Oligonucleotide Sequences Required for Natural Killer Cell Activation
Kuramoto, E., Yano, O., Kimura, Y., Baba, M., Makino, T., Yamamoto, S., Yamamoto, T., Kataoka, T., & Tokunaga, T. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb02734.x · Cited by 128 · see citing works
Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1
Zhang, R., Diasio, R. B., Lu, Z., Liu, T., Jiang, Z., Galbraith, W. M., & Agrawal, S. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00010-w · Cited by 125 · see citing works
Pyranosyl‐RNA (‘p‐RNA’): Base‐pairing selectivity and potential to replicate. Preliminary communication
Pitsch, S., Krishnamurthy, R., Bolli, M., Wendeborn, S., Holzner, A., Minton, M., Lesueur, C., Schlönvogt, I., Jaun, B., & Eschenmoser, A. (1995) · Helvetica Chimica Acta · doi:10.1002/hlca.19950780702 · Cited by 123 · see citing works
Inhibition of Coagulation by a Phosphorothioate Oligonucleotide
Henry, S. P., Novotny, W. F., LEEDS, J., Auletta, C. S., & Kornbrust, D. J. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.503 · Cited by 122 · see citing works
α-DNA VI: comparative study of α- and β-anomeric oligodeoxyribonucleotides in hybridization to mRNA and in cell free translation inhibition
Gagnor, C., Bertrand, J.-R., Thenet, S., Lemaitre, M. M., Morvan, F., Rayner, B., Malvy, C., Lebleu, B., Imbach, J., & Paoletti, C. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.24.10419 · Cited by 121 · see citing works
Carbohydrate Modifications in Antisense Research
Sanghvi, Y. S., & Cook, P. D. (1994) · ACS symposium series · doi:10.1021/bk-1994-0580 · Cited by 120 · see citing works
In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
Crooke, R. M. (1991) · PubMed · Cited by 120 · see citing works
Progress toward oligonucleotide therapeutics: pharmacodynamic properties
Crooke, S. T. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.6.7682523 · Cited by 119 · see citing works
Phosphorothioate Oligonucleotides Inhibit the Intrinsic Tenase Complex
Sheehan, J. P., & Lan, H.-C. (1998) · Blood · doi:10.1182/blood.v92.5.1617 · Cited by 118 · see citing works
Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys
Henry, S. P., Bolte, H. F., Auletta, C. S., & Kornbrust, D. J. (1997) · Toxicology · doi:10.1016/s0300-483x(97)03661-5 · Cited by 118 · see citing works
Binding Affinity and Specificity of Escherichia coli RNase H1: Impact on the Kinetics of Catalysis of Antisense Oligonucleotide−RNA Hybrids
Lima, W. F., & Crooke, S. T. (1997) · Biochemistry · doi:10.1021/bi962230p · Cited by 117 · see citing works
Importance of the positive charge cluster in Escherichia coli ribonuclease HI for the effective binding of the substrate
Kanaya, S., Katsuda-Nakai, C., & Ikehara, M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99002-2 · Cited by 116 · see citing works
Suppression of Neointimal Smooth Muscle Cell Accumulation in Vivo by Antisense cdc2 and cdk2 Oligonucleotides in Rat Carotid Artery
Abe, J., Zhou, W. J., Taguchi, J., Takuwa, N., Miki, K., Okazaki, H., Kurokawa, K., Kumada, M., & Takuwa, Y. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1003 · Cited by 115 · see citing works
N-(fluorenyl-9-methoxycarbonyl) amino acids, a class of antiinflammatory agents with a different mechanism of action.
Burch, R. M., Weitzberg, M., Blok, N., Muhlhauser, R. O., Martin, D., Farmer, S. G., Bator, J. M., Connor, J. R., Green, M., & Ko, C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.2.355 · Cited by 115 · see citing works
The Dopamine Transporter and Cocaine Medication Development: Drug Self-Administration in Nonhuman Primates
Howell, L. L., & Wilcox, K. M. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29344-7 · Cited by 115 · see citing works
Ribonuclease H from K562 human erythroleukemia cells. Purification, characterization, and substrate specificity.
Eder, P. S., & Walder, J. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)38142-0 · Cited by 114 · see citing works
5-Heteroaryl-2'-deoxyuridine Analogs. Synthesis and Incorporation into High-Affinity Oligonucleotides
Gutierrez, A. J., Terhorst, T. J., Matteucci, M. D., & Froehler, B. C. (1994) · Journal of the American Chemical Society · doi:10.1021/ja00092a003 · Cited by 112 · see citing works
Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats.
Cossum, P. A., Truong, L., Owens, S. R., Markham, P. M., Shea, J. P., & Crooke, S. T. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38714-8 · Cited by 110 · see citing works
Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin
Srinivasan, S. K., Tewary, H. K., & Iversen, P. L. (1995) · Antisense Research and Development · doi:10.1089/ard.1995.5.131 · Cited by 109 · see citing works
In Vivo Toxicological Effects of rel A Antisense Phosphorothioates in CD-1 Mice
Sarmiento, U. M., Perez, J. R., BECKER, J. M., & Narayanan, R. (1994) · Antisense Research and Development · doi:10.1089/ard.1994.4.99 · Cited by 109 · see citing works
Antisense Research and Application
Crooke, S. T. (1998) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-58785-6 · Cited by 109 · see citing works
Detection of Ribonuclease H-Generated mRNA Fragments in Human Leukemia Cells Following Reversible Membrane Permeabilization in the Presence of Antisense Oligodeoxynucleotides
Giles, R. V., Spiller, D. G., & TIDD, D. M. (1995) · Antisense Research and Development · doi:10.1089/ard.1995.5.23 · Cited by 108 · see citing works
In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.
Crooke, R. M., Graham, M. J., Cooke, M. E., & Crooke, S. T. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12072-7 · Cited by 107 · see citing works
Synthesis and duplex stability of oligonucleotides containing cytosine-thymine analogues
Lin, P. K. T., & Brown, D. M. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.24.10373 · Cited by 101 · see citing works
Efficient sequence-specific cleavage of RNA using novel europium complexes conjugated to oligonucleotides
Hall, J., Hüsken, D., Pieles, U., Moser, H. E., & Häner, R. (1994) · Chemistry & Biology · doi:10.1016/1074-5521(94)90008-6 · Cited by 99 · see citing works
Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3',5'-blocked oligonucleotides.
Sands, H., Gorey‐Feret, L. J., HO, S. P., Bao, Y., Cocuzza, A. J., Chidester, D. R., & Hobbs, F. W. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08583-9 · Cited by 99 · see citing works
Functional group substitutions as probes of hydrogen bonding between GA mismatches in RNA internal loops
SantaLucia, J., Kierzek, R., & Turner, D. H. (1991) · Journal of the American Chemical Society · doi:10.1021/ja00011a039 · Cited by 98 · see citing works
In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats
Zhang, R., Lu, Z., Zhao, H., Zhang, X., Diasio, R. B., Habuš, I., Jiang, Z., Iyer, R. P., Dong, Y. J., & Agrawal, S. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00159-w · Cited by 97 · see citing works
In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue.
Iversen, P. L. (1991) · PubMed · Cited by 95 · see citing works
Pseudo—Half-Knot Formation with RNA
Ecker, D. J., Vickers, T. A., Bruice, T. W., Freier, S., Jenison, R. D., Manoharan, M., & Zounes, M. C. (1992) · Science · doi:10.1126/science.1502560 · Cited by 94 · see citing works
In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts
Cowsert, L. M., Fox, M., Zon, G., & Mirabelli, C. K. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.2.171 · Cited by 94 · see citing works
Evaluation of the Toxicity of ISIS 2302, a Phosphorothioate Oligonucleotide, in a 4-Week Study in CD-1 Mice
Henry, S. P., TAYLOR, J., MIDGLEY, L., Levin, A. A., & Kornbrust, D. J. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.473 · Cited by 94 · see citing works
In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum.
Zhou, L.-W., Zhang, S., Qin, Z., & Weiss, B. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38956-1 · Cited by 92 · see citing works
Oligodeoxynucleotides Enhance Lipopolysaccharide-Stimulated Synthesis of Tumor Necrosis Factor: Dependence on Phosphorothioate Modification and Reversal by Heparin
Hartmann, G., Krug, A., Waller-Fontaine, K., & Endres, S. (1996) · Molecular Medicine · doi:10.1007/bf03401902 · Cited by 88 · see citing works
Biologic and therapeutic significance of MYB expression in human melanoma.
Hijiya, N., Zhang, J., Ratajczak, M. Z., Kant, J. A., DeRiel, K., Herlyn, M., Zon, G., & Gewirtz, A. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4499 · Cited by 84 · see citing works
Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4.
Stein, C. A., Neckers, L. M., Nair, B. C., Mumbauer, S. W., Hoke, G., & Pal, R. (1991) · PubMed · Cited by 83 · see citing works
A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures
Matveeva, O. V. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.5010 · Cited by 82 · see citing works
A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts
Crooke, S. T., Grillone, L. R., Tendolkar, A. V., Garrett, A., Fratkin, M. J., Leeds, J. M., & Barr, W. H. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.189 · Cited by 80 · see citing works
Pharmacokinetics, Biodistribution, and Stability of Capped Oligodeoxynucleotide Phosphorothioates in Mice
Temsamani, J., Tang, J. Y., Padmapriya, A. A., Kubert, M., & Agrawal, S. (1993) · Antisense Research and Development · doi:10.1089/ard.1993.3.277 · Cited by 75 · see citing works
In vitro and in vivo pharmacologic activities of antisense oligonucleotides.
Mirabelli, C. K., Cf, B., Anderson, K., & St, C. (1991) · PubMed · Cited by 75 · see citing works
Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA
Weiss, B., Zhou, L.-W., Zhang, S. P., & Qin, Z. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90426-g · Cited by 74 · see citing works
Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines
Sanghvi, Y. S., Hoke, G. D., Freier, S. M., Zounes, M. C., Gonzalez, C., Cummins, L. L., Sasmor, H. M., & Cook, P. D. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.14.3197 · Cited by 73 · see citing works
Number and distribution of methyiphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates
Quartin, R. S., Brakel, C. L., & Wetmur, G. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.18.7253 · Cited by 71 · see citing works
Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.
Burch, R. M., & Mahan, L. C. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115421 · Cited by 71 · see citing works
Cloning of the cDNA encoding the large subunit of human RNase HI, a homologue of the prokaryotic RNase HII
Frank, P. H., Braunshofer-Reiter, C., Wintersberger, U., Grimm, R., & Büsen, W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.12872 · Cited by 68 · see citing works
Cleavage of Single Strand RNA Adjacent to RNA-DNA Duplex Regions by Escherichia coli RNase H1
Lima, W. F., & Crooke, S. T. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.27513 · Cited by 67 · see citing works
New synthetic routes to synthons suitable for 2′-O-allyloligoribonucleotide assembly
Sproat, B. S., Iribarre, A. M., Garcı́a, R. G., & Beijer, B. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.4.733 · Cited by 67 · see citing works
Basic Principles of Antisense Therapeutics
Crooke, S. T. (1998) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-58785-6_1 · Cited by 66 · see citing works
α-DNA IX: parallel annealing of α-anomeric oligodeoxyribonucleotides to natural mRNA is required for interference in RNase H mediated hydrolysis and reverse transcription
Gagnor, C., Rayner, B., Léonetti, J., Imbach, J., & Leblcu, B. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.13.5107 · Cited by 66 · see citing works
Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus
Pisetsky, D. S., & Reich, C. F. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00780-2 · Cited by 65 · see citing works
Tritium labeling of antisense oligonucleotides by exchange with tritiated water
Graham, M. J., Freier, S., Crooke, R. M., Ecker, D. J., Maslova, R. N., & Lesnik, E. A. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.16.3737 · Cited by 63 · see citing works
Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.
Henry, S. P., Monteith, D. K. B., & Levin, A. A. (1997) · PubMed · Cited by 62 · see citing works
Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translationin vitro
Crum, C., Johnson, J. D., Nelson, A., & Roth, D. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.10.4569 · Cited by 61 · see citing works
Pharmacokinetic and Toxicity Profile of a Phosphorothioate Oligonucleotide Following Inhalation Delivery to Lung in Mice
Templin, M. V., Levin, A. A., Graham, M. J., Åberg, P. M., AXELSSON, B. I., Butler, M., Geary, R. S., & Bennett, C. F. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.359 · Cited by 60 · see citing works
In Vivo Modulation of N- myc Expression by Continuous Perfusion with an Antisense Oligonucleotide
Whitesell, L. J., ROSOLEN, A., & NECKERS, L. M. (1991) · Antisense Research and Development · doi:10.1089/ard.1991.1.343 · Cited by 58 · see citing works
A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the angiotensin AT1 receptor
Ambühl, P., Gyurko, R., & Phillips, M. I. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00092-p · Cited by 57 · see citing works
Molecular Cloning and Expression of cDNA for Human RNase H
Wu, H., Lima, W. F., & Crooke, S. T. (1998) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1998.8.53 · Cited by 57 · see citing works
The Induction of Interferon by Natural and Synthetic Polynucleotides
Colby, C. (1971) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60324-4 · Cited by 55 · see citing works
Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line.
Rosolen, A., Whitesell, L. J., Ikegaki, N., Kennett, R. H., & Neckers, L. M. (1990) · PubMed · Cited by 55 · see citing works
O-108 Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC
Lynch, T. J., Raju, R., Lind, M., Riviere, A., Gatzemeier, U., Dorr, A., Holmlund, J., Yuen, A. R., & Sikic, B. I. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)91766-1 · Cited by 54 · see citing works
Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression
Barton, C. M., & Lemoine, N. R. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.88 · Cited by 52 · see citing works
The Influence of Antisense Oligonucleotide-induced RNA Structure on Escherichia coli RNase H1 Activity
Lima, W. F., Mohan, V., & Crooke, S. T. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.18191 · Cited by 52 · see citing works
Absolute Bioavailability of 2′-O-(2-Methoxyethyl)-Modified Antisense Oligonucleotides following Intraduodenal Instillation in Rats
Geary, R. S., Khatsenko, O. G., Bunker, K., Crooke, R. M., Moore, M., Burckin, T., Truong, L., Sasmor, H. M., & Levin, A. A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38832-9 · Cited by 49 · see citing works
Oligodeoxynucleotide antisense to the D1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine.
Zhang, S. P., Zhou, L.-W., & Weiss, B. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24032-0 · Cited by 48 · see citing works
Toxicity of Antisense Oligonucleotides
Levin, A. A., Henry, S. P., Monteith, D., & Templin, M. V. (2001) · CRC Press eBooks · doi:10.1201/9781420002546.ch9 · Cited by 48 · see citing works
In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats
Zhang, R., Lu, Z., Zhang, X., Zhao, H., Diasio, R. B., Liu, T., Jiang, Z., & Agrawal, S. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.6.836 · Cited by 47 · see citing works
Toxicity of Oligodeoxynucleotide Therapeutic Agents
Levin, A. A., Monteith, D., Leeds, J. M., Nicklin, P. L., Geary, R. S., Butler, M., Templin, M. V., & Henry, S. P. (1998) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-58785-6_5 · Cited by 46 · see citing works
Interaction of Oligodeoxynucleotides with Mammalian Cells
HAWLEY, P., & Gıbson, I. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.185 · Cited by 46 · see citing works
Stability and Pharmacokinetic Characteristics of Oligonucleotides Modified at Terminal Linkages in Mice
MIYAO, T., Takakura, Y., Akiyama, T., Yoneda, F., Sezaki, H., & Hashida, M. (1995) · Antisense Research and Development · doi:10.1089/ard.1995.5.115 · Cited by 44 · see citing works
Specific inhibition of cell-surface T-cell receptor expression by antisense oligodeoxynucleotides and its effect on the production of an antigen-specific regulatory T-cell factor.
Zheng, H., Sahai, B. M., Kilgannon, P., Fotedar, A., & Green, D. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3758 · Cited by 43 · see citing works
Synthesis and hybridization of dodecadeoxyribonucleotides containing a fluorescent pyridopyrimidine deoxynucleoside
Inoue, H., Imura, A., & Ohtsuka, E. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.19.7119 · Cited by 43 · see citing works
Therapeutic modulation of cytokines.
Henderson, B. E. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.6.519 · Cited by 42 · see citing works
Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats
Henry, S. P., Grillone, L. R., Orr, J. L., Bruner, R. H., & Kornbrust, D. J. (1997) · Toxicology · doi:10.1016/s0300-483x(96)03532-9 · Cited by 42 · see citing works
Control of Gene Expression by Oligodeoxynucleotides Covalently Linked to Intercalating Agents and Nucleic Acid-cleaving Reagents
Hélène, C., & Toulmé, J. (1989) · doi:10.1007/978-1-349-10869-5_8 · Cited by 42 · see citing works
Non-ionic Antisense Oligonucleotides
Miller, P. S. (1989) · doi:10.1007/978-1-349-10869-5_5 · Cited by 41 · see citing works
Toxicological properties of several novel oligonucleotide analogs in mice.
Henry, S. P., Zuckerman, J., Rojko, J. L., Hall, W. C., Harman, R. J., Kitchen, D., & Crooke, S. T. (1997) · PubMed · Cited by 39 · see citing works
Therapeutic Applications of Oligonucleotides
Crooke, S. T. (1992) · Nature Biotechnology · doi:10.1038/nbt0892-882 · Cited by 38 · see citing works
Modulation of eucaryotic initiation factor-4E binding to 5'-capped oligoribonucleotides by modified anti-sense oligonucleotides.
Baker, B. F., Miraglia, L. J., & Hagedorn, C. H. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49937-7 · Cited by 37 · see citing works
Oligonucleotide Pharmacotherapy: An Antigene Strategy
Nagel, K. M., Holstad, S. G., & Isenberg, K. E. (1993) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1993.tb02723.x · Cited by 37 · see citing works
DETERMINATION OF BINDING CONSTANTS OF SERUM ALBUMIN FOR PENICILLIN
Joos, R. W., & Hall, W. H. (1969) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)28211-8 · Cited by 37 · see citing works
Microinjected oligonucleotides complementary to the alpha-sarcin loop of 28 S RNA abolish protein synthesis in Xenopus oocytes.
Saxena, S. K., & Ackerman, E. J. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39762-5 · Cited by 36 · see citing works
Use of Cationic Lipids to Enhance the Biological Activity of Antisense Oligonucleotides
Bennett, C. F., Chiang, M.-Y., Chan, H., & Grimm, S. (1993) · Journal of Liposome Research · doi:10.3109/08982109309147445 · Cited by 36 · see citing works
Uptake Characteristics of Oligonucleotides in the Isolated Rat Liver Perfusion System
Takakura, Y., Mahato, R. I., YOSHIDA, M., Kanamaru, T., & Hashida, M. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.177 · Cited by 36 · see citing works
Cholesteryl-Conjugated Phosphorothioate Oligodeoxynucleotides Modulate CYP2B1 ExpressionIn Vivo
Desjardins, J. P., Mata, J. E., Brown, T., Graham, D., Zon, G., & Iversen, P. L. (1995) · Journal of drug targeting · doi:10.3109/10611869509015917 · Cited by 35 · see citing works
Preclinical Evaluation of the Effects of a Novel Antisense Compound Targeting C-rafKinase in Mice and Monkeys
Monteith, D. K. B. (1998) · Toxicological Sciences · doi:10.1006/toxs.1998.2527 · Cited by 35 · see citing works
D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.
Qin, Z., Zhou, L.-W., Zhang, S., Wang, Y., & Weiss, B. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10528-2 · Cited by 35 · see citing works

Flagged first, then by citations

2 of the 243 references couldn’t be matched to a known paper.

Sorted by citations

Lipid-induced insulin resistance: unravelling the mechanism
Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60408-4 · Cited by 1,189 · see citing works
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 864 · see citing works
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677 · see citing works
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521 · see citing works
Alternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527 · see citing works
Long non-coding RNAs: From disease code to drug role
Chen, Y., Li, Z., Chen, X., & Zhang, S. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.001 · Cited by 500 · see citing works
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506 · see citing works
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 456 · see citing works
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Juliano, R. L., Alam, M. R., Dixit, V., & Kang, H. M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 430 · see citing works
ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION
Chan, J. H. P., Lim, S., & Wong, W. S. F. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04403.x · Cited by 431 · see citing works
Myocarditis
Fung, G., Luo, H., Qiu, Y., Yang, D., & McManus, B. (2016) · Circulation Research · doi:10.1161/circresaha.115.306573 · Cited by 444 · see citing works
Molecular Mechanisms of Antisense Oligonucleotides
Crooke, S. T. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0656 · Cited by 404 · see citing works
RNA interference: From gene silencing to gene-specific therapeutics
Leung, R. K. M., & Whittaker, P. A. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.03.004 · Cited by 382 · see citing works
Natural and engineered nucleic acids as tools to explore biology
Breaker, R. R. (2004) · Nature · doi:10.1038/nature03195 · Cited by 361 · see citing works
Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B
Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J. Q., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J., & Crooke, R. M. (2006) · Circulation · doi:10.1161/circulationaha.105.606442 · Cited by 356 · see citing works
siRNA-based approaches in cancer therapy
Devi, G. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700931 · Cited by 354 · see citing works
RNA Interference: From Basic Research to Therapeutic Applications
Kurreck, J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802092 · Cited by 332 · see citing works
Diacylglycerol Activation of Protein Kinase Cε and Hepatic Insulin Resistance
Jornayvaz, F. R., & Shulman, G. I. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.005 · Cited by 315 · see citing works
Biological Barriers to Therapy with Antisense and siRNA Oligonucleotides
Juliano, R. L., Bauman, J. A., Kang, H. M., & Ming, X. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900093r · Cited by 306 · see citing works
Nano-flares for mRNA Regulation and Detection
Prigodich, A. E., Seferos, D. S., Massich, M. D., Giljohann, D. A., Lane, B. C., & Mirkin, C. A. (2009) · ACS Nano · doi:10.1021/nn9003814 · Cited by 284 · see citing works
Fructose induced lipogenesis: from sugar to fat to insulin resistance
Samuel, V. T. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.10.003 · Cited by 261 · see citing works
Theranostic DNAzymes
Zhou, W., Ding, J., & Liu, J. (2017) · Theranostics · doi:10.7150/thno.17736 · Cited by 252 · see citing works
Recent developments in oligonucleotide conjugation
Singh, Y., Murat, P., & Defrancq, É. (2010) · Chemical Society Reviews · doi:10.1039/b911431a · Cited by 251 · see citing works
The involvement of microRNAs in neurodegenerative diseases
Maciotta, S., Meregalli, M., & Torrente, Y. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00265 · Cited by 247 · see citing works
Therapeutic potential of nanoparticulate systems for macrophage targeting
Chellat, F., Merhi, Y., Moreau, A., & Yahia, L. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.05.044 · Cited by 237 · see citing works
Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies
Vucic, S., Rothstein, J. D., & Kiernan, M. C. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.05.006 · Cited by 223 · see citing works
PEG-Modified Carbon Nanotubes in Biomedicine: Current Status and Challenges Ahead
Bottini, M., Rosato, N., & Bottini, N. (2011) · Biomacromolecules · doi:10.1021/bm201020h · Cited by 220 · see citing works
Design of a small molecule against an oncogenic noncoding RNA
Velagapudi, S. P., Cameron, M. D., Haga, C. L., Rosenberg, L. H., Lafitte, M., Duckett, D. R., Phinney, D. G., & Disney, M. D. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523975113 · Cited by 220 · see citing works
Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue
Kiefer, F. W., Vernochet, C., O’Brien, P., Spoerl, S., Brown, J. D., Nallamshetty, S., Zeyda, M., Stulnig, T. M., Cohen, D. E., Kahn, C. R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2757 · Cited by 210 · see citing works
Tat-Conjugated PAMAM Dendrimers as Delivery Agents for Antisense and siRNA Oligonucleotides
Kang, H. M., DeLong, R. K., Fisher, M. H., & Juliano, R. L. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8330-5 · Cited by 197 · see citing works
A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy
Mäe, M. A., Andaloussi, S. E., Lundin, P., Oskolkov, N., Johansson, H. J., Guterstam, P., & Langel, Ü. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.11.025 · Cited by 188 · see citing works
Solid-Phase Synthesis of Oligonucleotide Conjugates Useful for Delivery and Targeting of Potential Nucleic Acid Therapeutics
Lönnberg, H. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800406a · Cited by 188 · see citing works
Particle size affects the cellular response in macrophages
Yue, H., Wei, W., Yue, Z., Lv, P., Wang, L., Ma, G., & Su, Z. G. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.09.006 · Cited by 185 · see citing works
Distinct Uptake Routes of Cell-Penetrating Peptide Conjugates
Lundin, P., Johansson, H. J., Guterstam, P., Holm, T., Hansen, M., Langel, Ü., & Andaloussi, S. E. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800212j · Cited by 183 · see citing works
Genetic medicines: treatment strategies for hereditary disorders
O’Connor, T. P., & Crystal, R. G. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1829 · Cited by 180 · see citing works
A Novel Cell-penetrating Peptide, M918, for Efficient Delivery of Proteins and Peptide Nucleic Acids
Andaloussi, S. E., Johansson, H. J., Holm, T., & Langel, Ü. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300255 · Cited by 170 · see citing works
The tale of RNA G-quadruplex
Agarwala, P., Pandey, S., & Maiti, S. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02681k · Cited by 168 · see citing works
Thermodynamic, Counterion, and Hydration Effects for the Incorporation of Locked Nucleic Acid Nucleotides into DNA Duplexes
Kaur, H., Arora, A., Wengel, J., & Maiti, S. (2006) · Biochemistry · doi:10.1021/bi060307w · Cited by 168 · see citing works
Design, Synthesis, and Properties of 2‘,4‘-BNA NC : A Bridged Nucleic Acid Analogue
Rahman, S. M. A., Seki, S., Obika, S., Yoshikawa, H., Miyashita, K., & Imanishi, T. (2008) · Journal of the American Chemical Society · doi:10.1021/ja710342q · Cited by 164 · see citing works
Antisense Drug Discovery and Development
Yamamoto, T., Nakatani, M., Narukawa, K., & Obika, S. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.2 · Cited by 155 · see citing works
Lipid Conjugated Oligonucleotides: A Useful Strategy for Delivery
Raouane, M., Desmaële, D., Urbinati, G., Massaad-Massade, L., & Couvreur, P. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200422w · Cited by 154 · see citing works
Artificial ribonucleases
Niittymäki, T., & Lönnberg, H. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b509022a · Cited by 147 · see citing works
Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity
Marcucci, G., Stock, W., Dai, G., Klisovic, R. B., Liu, S., Klisovic, M. I., Blum, W. G., Kefauver, C. A., Sher, D. A., Green, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.118 · Cited by 141 · see citing works
Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG Repeat
Gagnon, K. T., Pendergraff, H. M., Deleavey, G. F., Swayze, E. E., Potier, P., Randolph, J., Roesch, E. B., CHATTOPADHYAYA, J. B., Damha, M. J., Bennett, C. F., et al. (2010) · Biochemistry · doi:10.1021/bi101208k · Cited by 139 · see citing works
Chirality as a tool in nucleic acid recognition: Principles and relevance in biotechnology and in medicinal chemistry
Corradini, R., Sforza, S., Tedeschi, T., & Marchelli, R. (2007) · Chirality · doi:10.1002/chir.20372 · Cited by 136 · see citing works
Fully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve Glucose Homeostasis in Mice and Monkeys
Yan, H., Gu, W., Yang, J., Bi, V., Shen, Y., Lee, E. K., Winters, K. A., Komorowski, R., Zhang, C., Patel, J., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.147009 · Cited by 134 · see citing works
Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
Graham, M. J., Viney, N., Crooke, R. M., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r052258 · Cited by 133 · see citing works
Identification and validation of cell surface antigens for antibody targeting in oncology
Carter, P. M., Smith, L. M., & Ryan, M. C. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00766 · Cited by 129 · see citing works
Selective Enhancement of Nucleases by Polyvalent DNA-Functionalized Gold Nanoparticles
Prigodich, A. E., Alhasan, A. H., & Mirkin, C. A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja110833r · Cited by 127 · see citing works
A Phase II dose ranging, double‐blind, placebo‐controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left‐sided ulcerative colitis
van Deventer, S. J. H., Wedel, M. K., Baker, B. F., Xia, S., Chuang, E., & Miner, P. B. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02910.x · Cited by 127 · see citing works
Characterization of Target mRNA Reduction Through In Situ RNA Hybridization in Multiple Organ Systems Following Systemic Antisense Treatment in Animals
Hung, G., Xiao, X., Peralta, R. Q., Bhattacharjee, G., Murray, S., Norris, D., Guo, S., & Monia, B. P. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0443 · Cited by 126 · see citing works
miRNAs: Key Players in Neurodegenerative Disorders and Epilepsy
Karnati, H. K., Panigrahi, M. K., Gutti, R. K., Greig, N. H., & Tamargo, I. A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150395 · Cited by 125 · see citing works
Layer-by-Layer Assembled Antisense DNA Microsponge Particles for Efficient Delivery of Cancer Therapeutics
Roh, Y. H., Lee, J. B., Shopsowitz, K. E., Dreaden, E. C., Morton, S. W., Poon, Z., Hong, J., Yamin, I., Bonner, D. K., & Hammond, P. T. (2014) · ACS Nano · doi:10.1021/nn502596b · Cited by 125 · see citing works
Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis
Alam, M. R., Dixit, V., Kang, H. M., Li, Z., Chen, X. S., Trejo, J., Fisher, M. H., & Juliano, R. L. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn115 · Cited by 124 · see citing works
Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
Fusco, D. D., Dinallo, V., Marafini, I., Figliuzzi, M. M., Romano, B., & Monteleone, G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00305 · Cited by 123 · see citing works
Cell-penetrating-peptide-based delivery of oligonucleotides: an overview
Abes, R., Arzumanov, A. A., Moulton, H. M., Abes, S., Ivanova, G. D., Iversen, P. L., Gait, M. J., & Lebleu, B. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350775 · Cited by 122 · see citing works
Opportunities for yeast metabolic engineering: Lessons from synthetic biology
Krivoruchko, A., Siewers, V., & Nielsen, J. (2011) · Biotechnology Journal · doi:10.1002/biot.201000308 · Cited by 121 · see citing works
Brothers in Arms
Bhindi, R., Fahmy, R. G., Lowe, H. C., Chesterman, C. N., Dass, C. R., Cairns, M. J., Saravolac, E. G., Sun, L., & Khachigian, L. M. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070120 · Cited by 119 · see citing works
Frameworks for Programming Biological Function through RNA Parts and Devices
Win, M. N., Liang, J. C., & Smolke, C. D. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.02.011 · Cited by 119 · see citing works
MicroRNAs as targets for antisense-based therapeutics
Stenvang, J., & Kauppinen, S. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.1.59 · Cited by 115 · see citing works
Δ-5 Fatty Acid Desaturase <i>FADS1</i> Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators
Gromovsky, A. D., Schugar, R. C., Brown, A. L., Helsley, R. N., Burrows, A. C., Ferguson, D., Zhang, R., Sansbury, B. E., Lee, R. G., Morton, R. E., et al. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309660 · Cited by 115 · see citing works
Advances in Antisense Oligonucleotide Development for Target Identification, Validation, and as Novel Therapeutics
Mansoor, M., & Melendez, A. J. (2008) · Gene Regulation and Systems Biology · doi:10.4137/grsb.s418 · Cited by 115 · see citing works
Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Brautbar, A., & Ballantyne, C. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.2 · Cited by 114 · see citing works
Small molecule-mediated inhibition of translation by targeting a native RNA G-quadruplex
Bugaut, A., Rodriguez, R., Kumari, S., Hsu, S. D., & Balasubramanian, S. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c002418j · Cited by 109 · see citing works
Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis
Dorst, J., Ludolph, A. C., & Huebers, A. (2017) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617734734 · Cited by 106 · see citing works
Nucleic Acids as Therapeutic Agents
Álvarez-Salas, L. M. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608786141133 · Cited by 105 · see citing works
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left‐sided ulcerative colitis: a randomized, double‐blind, active‐controlled trial
Miner, P. B., Wedel, M. K., Xia, S., & Baker, B. F. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02837.x · Cited by 104 · see citing works
Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes
Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 99 · see citing works
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht088 · Cited by 99 · see citing works
The role of TGF-β in bone metastasis: novel therapeutic perspectives
Buijs, J. T., Stayrook, K. R., & Guise, T. A. (2012) · BoneKEy Reports · doi:10.1038/bonekey.2012.96 · Cited by 97 · see citing works
Transferrin Receptor-Targeted Lipid Nanoparticles for Delivery of an Antisense Oligodeoxyribonucleotide against Bcl-2
Yang, X., Koh, C. G., Liu, S., Pan, X., Santhanam, R., Yu, B., Peng, Y., Pang, J., Golan, S., Talmon, Y., et al. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800149s · Cited by 97 · see citing works
Innovative nanotechnologies for the delivery of oligonucleotides and siRNA
Toub, N., Malvy, C., Fattal, E., & Couvreur, P. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.07.093 · Cited by 96 · see citing works
Aptamers Embedded in Polyacrylamide Nanoparticles: A Tool for in Vivo Metabolite Sensing
Nielsen, L. J., Olsen, L. F., & Özalp, V. C. (2010) · ACS Nano · doi:10.1021/nn100635j · Cited by 95 · see citing works
MicroRNAs in parasitic diseases: Potential for diagnosis and targeting
Manzano-Román, R., & Siles‐Lucas, M. (2012) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2012.10.001 · Cited by 94 · see citing works
Genetic modification of stem cells for transplantation.
Phillips, M., & Tang, Y.-L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.035 · Cited by 84 · see citing works
Inhibition of UCP2 expression reverses diet‐induced diabetes mellitus by effects on both insulin secretion and action
DeSouza, C. T., ARAUJO, E. P. D., Stoppiglia, L. F., Pauli, J. R., Ropelle, E. R., Rocco, S. A., Marin, R. M., Franchini, K. G., Carvalheira, J. B. C., Saad, M. J. A., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-7148com · Cited by 90 · see citing works
Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7
Niu, C., Prakash, T. P., Kim, A., Quach, J., Huryn, L. A., Yang, Y., Lopez, E., Jazayeri, A., Hung, G., Sopher, B. L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aap8677 · Cited by 89 · see citing works
The Role of TGF-β in Bone Metastases
Trivedi, T., Pagnotti, G. M., Guise, T. A., & Mohammad, K. S. (2021) · Biomolecules · doi:10.3390/biom11111643 · Cited by 91 · see citing works
Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides
White, P. J., Anastasopoulos, F., Pouton, C. W., & Boyd, B. J. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001021 · Cited by 87 · see citing works
Coagulation factor XI as a novel target for antithrombotic treatment
Löwenberg, E. C., Meijers, J. C. M., Monia, B. P., & Levi, M. M. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04031.x · Cited by 85 · see citing works
Preparation of a Multitopic Glycopeptide−Oligonucleotide Conjugate
Singh, Y., Renaudet, O., Defrancq, É., & Dumy, P. (2005) · Organic Letters · doi:10.1021/ol050134n · Cited by 85 · see citing works
Controlled delivery of antisense oligonucleotides: a brief review of current strategies
Zhao, X., Pan, F., Holt, C. M., Lewis, A. L., & Lu, J. R. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902992894 · Cited by 82 · see citing works
Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements
Bruno, I., Jin, W., & Cote, G. J. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh272 · Cited by 84 · see citing works
Recent Developments in Peptide-Based Nucleic Acid Delivery
Veldhoen, S., Laufer, S. D., & Restle, T. (2008) · International Journal of Molecular Sciences · doi:10.3390/ijms9071276 · Cited by 82 · see citing works
Transcriptome-Wide Off-Target Effects of Steric-Blocking Oligonucleotides
Holgersen, E. M., Gandhi, S., Zhou, Y., Kim, J., Vaz, B., Bogojeski, J. J., Bugno, M., Shalev, Z., Cheung-Ong, K., Gonçalves, J., et al. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0921 · Cited by 81 · see citing works
Biomineralized Cascade Enzyme-Encapsulated ZIF-8 Nanoparticles Combined with Antisense Oligonucleotides for Drug-Resistant Bacteria Treatment
Zhang, Y., Lai, L., Liu, Y., Chen, B., Yao, J., Zheng, P., Pan, Q., & Zhu, W. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c23808 · Cited by 81 · see citing works
Cellular uptake mechanisms and potential therapeutic utility of peptidic cell delivery vectors: Progress 2001–2006
Fischer, P. M. (2006) · Medicinal Research Reviews · doi:10.1002/med.20093 · Cited by 79 · see citing works
Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA
Mahato, R. I., Cheng, K., & Guntaka, R. V. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.1.3 · Cited by 78 · see citing works
Recent Progress in Chemically Modified siRNAs
Gaglione, M., & Messere, A. (2010) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955710791384036 · Cited by 77 · see citing works
The chl a fluorescence intensity is remarkably insensitive to changes in the chlorophyll content of the leaf as long as the chl a/b ratio remains unaffected
Dinç, E., Ceppi, M. G., Tóth, S. Z., Bottka, S., & Schansker, G. (2012) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.02.003 · Cited by 76 · see citing works
Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides
Wang, S., Allen, N., Vickers, T. A., Revenko, A. S., Sun, H., Liang, X., & Crooke, S. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky145 · Cited by 75 · see citing works
TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases
Buijs, J. T., Stayrook, K. R., & Guise, T. A. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0075-6 · Cited by 73 · see citing works
Five- and Six-Membered Conformationally Locked 2‘,4‘-Carbocyclicribo-Thymidines: Synthesis, Structure, and Biochemical Studies
Srivastava, P., Barman, J., Pathmasiri, W., Plashkevych, O., Wenska, M., & CHATTOPADHYAYA, J. B. (2007) · Journal of the American Chemical Society · doi:10.1021/ja071106y · Cited by 74 · see citing works
Role of TGF-β in breast cancer bone metastases
Chiechi, A., Waning, D. L., Stayrook, K. R., Buijs, J. T., Guise, T. A., & Mohammad, K. S. (2013) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2013.410a4003 · Cited by 73 · see citing works
In Vivo Delivery Aspects of miRNA, shRNA and siRNA
Khatri, N., Rathi, M. N., Baradia, D., Trehan, S., & Misra, A. R. (2012) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v29.i6.20 · Cited by 68 · see citing works
Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides
Wang, S., Sun, H., Tanowitz, M., Liang, X., & Crooke, S. T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw595 · Cited by 72 · see citing works
Utilization of Intrachain 4′-C-Azidomethylthymidine for Preparation of Oligodeoxyribonucleotide Conjugates by Click Chemistry in Solution and on a Solid Support
Kiviniemi, A., Virta, P., & Lönnberg, H. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800221p · Cited by 71 · see citing works
RNAi: a novel antisense technology and its therapeutic potential.
Dallas, A., & Vlassov, A. V. (2006) · PubMed · Cited by 71 · see citing works
Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides
Wang, S., Sun, H., Tanowitz, M., Liang, X., & Crooke, S. T. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx231 · Cited by 70 · see citing works
Recent Developments in the Application of Plasmid DNA-Based Vectors and Small Interfering RNA Therapeutics for Cancer
Meyer, M., & Wagner, E. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1062 · Cited by 69 · see citing works

Authors: Crooke, S. T.
Affiliations: Ionis Pharmaceuticals (United States) (US)
Corresponding author: Crooke, Stanley T.
ORCID: Crooke, Stanley T.
Venue: Annual Review of Medicine
Publisher: Annual Reviews
Published: 2004-02-01
Volume: 55
Issue: 1
Pages: 61-95
ISSN: 0066-4219 (ISSN-L)
1545-326X
DOI: 10.1146/annurev.med.55.091902.104408
OpenAlex: W2138668121
Cited by: 417
References: 243
Citations by year: 2026: 1 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 9 · 2018: 5 · 2017: 15 · 2016: 12 · 2015: 14 · 2014: 16 · 2013: 24 · 2012: 32
FWCI: 3.07
Type: journal article
Language: en
Open access: closed
Locations: Annual Review of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords: antisense technology, oligonucleotide analogues, RNA hybridization, RNA degradation, RNA splicing, antisense drug development, pharmacokinetics, toxicity, target validation
MeSH terms: Animals, Humans, Oligonucleotides, Antisense, Biomedical Technology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Progress in antisense technology

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks